XML 31 R21.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Major Customers, Partnerships and Strategic Alliances (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2018
Kite Pharma, Inc. ("Kite") [Member] |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement for the three and nine months ended September 30, 2018 were as follows (in thousands):
|  | September 30, 2018 |
|  | Three Months Ended |  |  | Nine Months Ended |
Revenue related to Kite Collaboration: |  |  |  |  |  |  |  |
Recognition of upfront fee |  | $ | 6,296 |  |  | $ | 12,249 |
Research services |  |  | 2,732 |  |  |  | 4,295 |
Total |  | $ | 9,028 |  |  | $ | 16,544 |
Pfizer [Member] |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement for the three and nine months ended September 30, 2018 and 2017 were as follows (in thousands):
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |
Revenue related to Pfizer Collaboration for SB-525: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Recognition of upfront fee |  | $ | 10,421 |  |  | $ | 6,624 |  |  | $ | 26,262 |  |  | $ | 10,384 |
Bioverativ Inc [Member] |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement for the three and nine months ended September 30, 2018 and 2017 were as follows (in thousands):
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |
Revenue related to Bioverativ agreement: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Recognition of upfront fee |  | $ | 1,094 |  |  | $ | 442 |  |  | $ | 3,432 |  |  | $ | 1,326 |
Research services |  |  | 1,146 |  |  |  | 2,959 |  |  |  | 7,707 |  |  |  | 7,736 |
Total |  | $ | 2,240 |  |  | $ | 3,401 |  |  | $ | 11,139 |  |  | $ | 9,062 |
Shire AG [Member] |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement for the three and nine months ended September 30, 2018 and 2017 were as follows (in thousands):
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |
Revenue related to Shire agreement: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Recognition of upfront fee |  | $ | — |  |  | $ | 1,166 |  |  | $ | — |  |  | $ | 2,333 |
Research services |  |  | — |  |  |  | 6 |  |  |  | — |  |  |  | 116 |
Total |  | $ | — |  |  | $ | 1,172 |  |  | $ | — |  |  | $ | 2,449 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BioverativIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_ShireAgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |